

ì

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

KBI-0016

Inventors:

Natarajan Ranganathan

Serial No.:

10/676,558

Filing Date:

September 30, 2003

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Title:

Enteric Dialysis Compositions and

Methods

I, Jane Massey Licata, Registration No. 32,257, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

On this date: December 18, 2003

Jane Massey Licata, Registration No. 32,257

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three

months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is attached hereto; or
 - () The fee of \$180.00 as set forth in \$1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/855,346, filed May 15, 2001, Serial No. 09/557,011, filed April 30, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (XX) All listed references are in the English language.

Respectfully submitted,

Janosspieeri

Jane Massey Licata Registration No. 32,257

Date: December 18, 2003

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 01

Form PTO-14 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No. Serial No. 10/676,558

Applicant Ranganathan et al.

Filing Date Sept. 30, 2003

Group
Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BA		erview of gut flora and ional Journal of Food Microbiology
	BB		ection from gastrointestinal of probiotics ¹⁻³ ", Am J. Clin Nutr
	ВC	,	fidobacteria and Lactobacilli in Exptl. Clin. Res. 2000 XXVI(3):95-
	BD	•	Role of Intestinal Perfusion in the Uremia", Trans. Amer. Soc. Artif. 2-295
	BE	. ~	en, "Probiotics:established effects Eur J Gastroenterol Hepatol 1999
	٠		
EXAMINER			DATE CONSIDERED